All News

drug,capsules,antibotic

Early Antibiotic Use Increases JIA Risk

Jack Cush, MD

A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of juvenile idiopathic arthritis (JIA), although infections during fetal life or childhood did not increase risk of JIA.

Read Article
Fever,temp,man,HA,thermometer

Canakinumab Use in Periodic Febrile Disorders

Jack Cush, MD

A retrospective records review of patients with periodic fever syndromes (PFS)  receiving IL-1 inhibitor treatment with canakinumab (CAN), shows CAN to be effective and safe in a variety of PFS patients.

Read Article
Pills.JIA_.png

Different Regimens but Equal Outcomes in Polyarticular JIA

Jack Cush, MD

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen.

Read Article
Cancer.risk_.jpg

Lymphoma in RA: Disease Activity Matters

MedPage Today

Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.

In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for lymphoma, with an odds ratio of 2.09 (95% CI 1.41-3.38), according to Gaetane Nocturne, MD, of Hôpital Bicêtre in Ile-de-France, and colleagues.

Read Article
RheumNow Podcast square

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

Jack Cush, MD

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

Read Article
RheumNow Podcast square

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

Jack Cush, MD

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article
tkr_0.JPG

Delays in Joint Replacement as JIA Patients Reach Adulthood

Jack Cush, MD

A retrospective cohort study examined the need for joint replacement surgery in juvenile idiopathic arthritis (JIA) and showed there has been a trend to delay arthroplasty over time. The JIA category, year of implant, and presence of complications significantly affected implant survivorship.

Read Article
A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of JIA, although infections during fetal life or childhood did not increase risk of JIA. #RheumNow https://t.co/aXFOxoOyF1 https://t.co/Md0zBm5Txl

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrosp. review of 10–24 yr olds w/ newly Dx #SLE shows 78% given steroid-sparing DMARDs by year 1; Most (69%) given HCQ & fewer (34%) given other immunosuppressants. Adults less likely to recv immDMARDs @1 yr https://t.co/aLi6FXlMd3

Links:

Dr. John Cush RheumNow ( View Tweet)

CARRA (Childhood Arthritis and Rheumatology Research Alliance) has compared 3 different treatment strategies for polyarticular JIA to identify the optimal time to biologic regimen. Read more… https://t.co/swXZ4FxB33 #RheumNow #medtwitter https://t.co/zqfd9IPeEf

Links:

Dr. John Cush RheumNow ( View Tweet)
NICE (UK) has recommended tofacitinib as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older. https://t.co/9iLqzo36aD

Links:

Dr. John Cush RheumNow ( View Tweet)

MMWR: COVID-19–hospitalization rates in kids & adolescents rose 5-fold late June–mid-Aug 2021 (w/ rise of Delta variant). Hospitalization rates were 10 times higher among unvaccinated than fully vaccinated adolescents. https://t.co/Qt5lj3Ycxb

Links:

Dr. John Cush RheumNow ( View Tweet)

500 Turkish pts from 4 pediatric rheum clinics. Oligoart. JIA (oJIA) was most common (39%), then enthesitisJIA (ERA-23%), RF neg polyarthritis (16%), RF+ poly (2.2%), Systemic JIA (16%), juvenile PsA (5.2%). Uveitis most common in oJIA (13%), then ERA (5%) https://t.co/a7O1RBM1xJ https://t.co/woSafvVsmA

Links:

Dr. John Cush RheumNow ( View Tweet)
500 Turkish pts from 4 pediatric rheum clinics. Oligoart. JIA (oJIA) was most common (39%), then enthesitisJIA (ERA-23%), RF neg polyarthritis (16%), RF+ poly (2.2%), Systemic JIA (16%), juvenile PsA (5.2%). Uveitis most common in oJIA (13%), then ERA (5%) https://t.co/a7O1RC3Cph https://t.co/jMsuUM9lWy

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa

Links:

Dr. John Cush RheumNow ( View Tweet)

European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa

Links:

Dr. John Cush RheumNow ( View Tweet)

In the week ending 8/12: 👧🏽121,427 pediatric #COVID19 cases (14.4% of all cases, 49 states) 🏥452 pediatric hospitalizations (24 states reporting) 💀7 pediatric deaths (43 states reporting) One death is too many.

Shematologist, MD acweyand ( View Tweet)

85 rheumatic kids RTX treated - New hypogammaglobulinemia in 27% w/in 18 mos AND 26% w/ infections (half being serious infx). Prior pulse steriods ups risk of inx (OR 15.3) and hypogamma (OR 3.9). Hypogamm predicts risk of SIE (OR 7.9)

Dr. John Cush RheumNow ( View Tweet)

The FDA has authorized baricitinib ALONE as treatment for COVID-19 hospitalized adults and pediatric patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) https://t.co/WMc78GmOLU

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×